Impact ledger
Twist Bioscience Corporation (TWST): the developments shaping its investment case
Follow the evidence affecting Twist Bioscience Corporation. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Twist Bioscience Corporation · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-20 · 6 reports
Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal
Channel: Direct revenue generation from partnership, validation of technology, potential for future milestones/royalties.
Bullish· 1-3m
2026-09-19 · 2 reports
Twist Bioscience partners with Eli Lilly on TuneLab AI discovery
Channel: Direct revenue generation from services, validation of technology, potential for future collaborations.
Bullish· 1-3m
Event impact log
8 events mapped to TWST since 2026-09-19. Evidence through 2026-09-20.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-20 | Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal | Direct revenue generation from partnership, validation of technology, potential for future milestones/royalties. | Bullish | 1-3m | 0.90 |
| 2026-09-20 | Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact | Direct revenue generation from partnership, validation of technology, potential for future collaborations. | Bullish | 1-3m | 0.90 |
| 2026-09-19 | Twist Bioscience partners with Eli Lilly on TuneLab AI discovery | Direct revenue generation from services, validation of technology, potential for future collaborations. | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery | Direct partnership revenue, external validation, and increased market visibility for synthetic biology platforms. | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Twist Bioscience Partners with Eli Lilly on AI Drug Discovery Platform | Direct partnership revenue and validation of technology platform. Potential for future licensing deals and increased market share in synthetic biology and antibody discovery services. | Bullish | 3-12m | 0.90 |
| 2026-09-19 | Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform | Direct revenue generation from partnership, validation of technology, potential for future deals. | Bullish | 1-3m | 0.90 |
| 2026-09-19 | Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery | Direct commercial platform validation and new revenue stream from partnership. | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration | Direct revenue generation from collaboration, validation of technology, potential for future partnerships. | Bullish | 1-3m | 0.90 |
Continue this research
Build your Twist Bioscience Corporation investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the TWST entity page →